MentionFox
Home › Executive changes › Atrium Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Leadership changes at Atrium Therapeutics, Inc. (2026)

Before you join, sell to or invest in Atrium Therapeutics, Inc.

MentionFox check on Atrium Therapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/atrium-therapeutics

Check Atrium Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Atrium Therapeutics, Inc.?

Who joined and who left Atrium Therapeutics, Inc.? 1 filing reported on 2026-02-27, each cited to the company's own filing.

As of November 14, 2026, Atrium Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 27, 2026 (Form 8-K, February 27, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Sessa Capital IM, L.P. also filed stake reports on 3 other companies ↓

Sell to companies like Atrium Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-02-27

Atrium Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-27. Every row below is cited to the filing it comes from, and this page adds each new change as Atrium Therapeutics, Inc. files it.

Also on the record for Atrium Therapeutics, Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G, by Sessa Capital IM, L.P.8.8% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by RA Capital Management, L.P.—5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc.8.6% of the class5%+ stakesSource
July 27, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.6.6% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by RA Capital Management, L.P.5.6% of the class5%+ stakesSource
April 27, 2026Stake report, Schedule 13G, by BlackRock, Inc.5.2% of the class5%+ stakesSource
April 8, 2026Stake report, Schedule 13G, by T. Rowe Price Associates, Inc.10% of the class5%+ stakesSource

Selling to them or working with them? See who runs Atrium Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Atrium Therapeutics, Inc. and the records around it.

Atrium Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Atrium Therapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Atrium Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Atrium Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    8 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-27Reportednot named in the filing8-K, 2026-02-27
Selling to Atrium Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Atrium Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Atrium Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Atrium Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at Atrium Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-02-27 · 8-K

Reported

On February 26, 2026, in connection with the Distribution, the following people were elected as directors: Carsten Boess W. Michael Flanagan Simona Skerjanec Troy Wilson Class I of the Board consists of Ms. Skerjanec and Mr. Boess, and their respective terms will expire at the Company's first annual meeting of stockholders to be held after the completion of the Distribution.

Also stated in this filing

  • Class II of the Board consists of Mr. Wilson and Mr. Flanagan, and their respective terms will expire at the Company's second annual meeting of stockholders to be held after the completion of the Distribution.
  • Mr. Boess, Ms. Skerjanec and Mr. Wilson were appointed to serve as members of the Audit Committee of the Board.
  • Ms. Boyce, Ms. Skerjanec and Mr. Wilson were appointed to serve as members of the Human Capital Management Committee of the Board.
  • Employment Agreements with Certain Executive Officers On February 26, 2026, the Company entered into employment agreements with each of the executive officers set forth above.
  • Certain Compensatory Plans As described in the Information Statement, certain compensatory plans in which the Company's executive officers and directors will participate have been adopted by the Company in connection with the Separation and Distribution.
  • The Company's 2026 Incentive Award Plan and 2026 Employee Stock Purchase Plan are each described in the Information Statement under "Executive Compensation - 2026 Incentive Award Plan," and "Executive Compensation - 2026 Employee Stock Purchase Plan," respectively.

Tools for this story

Each opens in a new tab, filled in for Atrium Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/atrium-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Atrium Therapeutics, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/atrium-therapeutics